Ann: Appendix 4C - quarterly, page-17

Sorry forgot to add to the last post a couple of items from the call that are some what new and could be revenue accretive over time.

1) Screenpoint / CAD  - If the deal is finalized VHT will receive a fee for clients that take the Screenpoint product. Not clear if that will add other providers like ICAD.

2) Surgical - Seems like this is the next cab of the rank - A product designed to help surgeons for mastectomy and reconstruction.

3)  Quantitative Imaging - Monitoring Change over time both for women undergoing treatment but also for clinical trials. (The clinical trials aspect is a new one to me but could be a very big market and the product is well suited for it). Quantitative Imaging has the potential to be a very significant revenue generator but not clear where this fits in the timeline. VHT would have a very good head start here given the standardization they are able to bring to images. No one is close to them in this regard at this point .... they probably have an 18 month head start in this area, at least.